Open AccessActivation of peroxisome proliferator activated receptor-gamma results in an atheroprotective apolipoprotein profile in HepG2 cells
Author(s) -
Diala Fare Dahabreh,
Jheem D. Medh
Publication year - 2012
Publication title -
advances in biological chemistry
Language(s) - English
Resource type - Journals
eISSN - 2162-2191
pISSN - 2162-2183
DOI - 10.4236/abc.2012.23026
Subject(s) - ciglitazone , endocrinology , medicine , apolipoprotein b , liver x receptor , ldl receptor , apolipoprotein e , receptor , peroxisome proliferator activated receptor , chemistry , cholesterol , biology , nuclear receptor , transcription factor , lipoprotein , biochemistry , disease , gene
Insulin resistance is linked to dyslipidemia, characterized by a decrease in high density lipoproteins and an increase in low density lipoproteins. Thiazolidinediones (TZDs) are insulin-sensitizing agents used to improve glycemic control in patients with type 2 diabetes. Recently, the safety of certain TZD regimens has been questioned because of associated adverse effects on the plasma lipid profile. We examined the effect of a TZD, Ciglitazone, on apolipoprotein synthesis and secretion in human liver HepG2 cells.